Sonic Healthcare Limited

For the first half of FY2026, Sonic Healthcare reported revenue of $5.445 billion, EBITDA of $907 million, net profit of $262 million, and EPS of AUD 0.531. Management said organic revenue growth was 5% and that adjusted EBITDA margins improved by 30 basis points year over year. Full-year guidance was maintained for EBITDA at $1.87 billion to $1.95 billion on a constant-currency basis, with depreciation now expected at $770 million to $780 million, interest expense guided to increase 15% year over year on a constant-currency basis, and an effective tax rate of 27%. The company also said the interim dividend will be AUD 0.45, up 2.3%, and that debt cover is 2.5x with $1 billion of headroom before the dividend payment.

Jim Newcombe framed the quarter around operating leverage, synergy capture, and disciplined capital management. He said management remains focused on EPS improvement, return on invested capital, and cost control, including labor, while the U.S. business undergoes an operating review and anatomical pathology rationalization. He was upbeat on the portfolio, repeatedly emphasizing strong medical leadership culture, organic growth, and the ability to translate operational discipline into shareholder returns.

Chris Wilks emphasized that the company remains within guidance and highlighted balance-sheet strength and capital flexibility. He pointed to a debt cover ratio of 2.5x, $1 billion of headroom before the interim dividend, and recent net debt increases tied to the LADR Group and Cairo Diagnostics acquisitions. He also said the Brisbane sale-and-leaseback is being launched, with the site having recently received an $80 million extension and the rent expected to be circa $25 million, while noting maintenance CapEx excluding properties is roughly 3% to 3.5% of revenue.

Analysts pressed on U.S. margin pressure, the Change Healthcare billing disruption, and whether the business might be strategically rethought; management said the review is operational, not a wholesale divestiture review, and that restructuring should help margins even though some costs will continue in H2. Questions also focused on German GOA reform risk, with management saying there is no certainty it proceeds and no clarity on timing or impact. On the Australian wage review, management said the phlebotomist impact is expected to be sub-$2 million this year, while the health-professionals component remains uncertain and may require offsetting funding discussions.